Rose Nicola J, Stickings Paul, Schepelmann Silke, Bailey Marc J A, Burns Chris
The National Institute for Biological Standards and Control, a Centre of the Medicines and Healthcare products Regulatory Agency, Division of Virology, Hertfordshire, United Kingdom.
The National Institute for Biological Standards and Control, a Centre of the Medicines and Healthcare products Regulatory Agency, Division of Bacteriology, Hertfordshire, United Kingdom.
NPJ Vaccines. 2021 Aug 12;6(1):100. doi: 10.1038/s41541-021-00368-7.
The past 18 months have seen an unprecedented approach to vaccine development in the global effort against the COVID-19 pandemic. The process from discovery research, through clinical trials and regulatory approval often takes more than 10 years. However, the critical need to expedite vaccine availability in the pandemic has meant that new approaches to development, manufacturing, and regulation have been required: this has necessitated many stages of product development, clinical trials, and manufacturing to be undertaken in parallel at a global level. Through the development of these innovative products, the world has the best chance of finding individual, or combinations of, vaccines that will provide adequate protection for the world's population. Despite the huge scientific and regulatory achievements and significant investment to accelerate vaccine availability, it is essential that safety measures are not compromised. Here we focus on the post regulatory approval testing by independent laboratories that provides an additional assurance of the safety and quality of a product, with an emphasis on the UK experience through the National Institute for Biological Standards and Control (NIBSC), an expert centre of the UK's Medicines and Healthcare products Regulatory Agency (MHRA).
在全球抗击新冠疫情的努力中,过去18个月见证了疫苗研发前所未有的方式。从发现研究到临床试验再到监管批准的过程通常需要十多年时间。然而,在疫情中加速疫苗供应的迫切需求意味着需要新的研发、生产和监管方法:这就要求在全球层面并行开展产品研发、临床试验和生产的多个阶段。通过这些创新产品的研发,世界最有可能找到能够为全球人口提供充分保护的单一疫苗或疫苗组合。尽管在加速疫苗供应方面取得了巨大的科学和监管成就以及大量投资,但确保安全措施不被削弱至关重要。在此,我们重点关注独立实验室在监管批准后的检测,这为产品的安全性和质量提供了额外保障,尤其强调英国国家生物标准与控制研究所(NIBSC)的经验,该研究所是英国药品和医疗产品监管局(MHRA)的一个专家中心。